

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax 0091-11-26498341, 26494708, Phone: 0091-11-46181100, 46109900
Email: cs@jagsonpal.com; nandita.singh@jagsonpal.com
CIN No. L74899DL1978PLC009181

July 16, 2022

The Department of Corporate Services-Listing

BSE Ltd,

Phiroze Jeejeebhoy Towers,

Dalal Street

Mumbai-400 001

Scrip Code: 507789

National Stock Exchange of India Ltd

Exchange Plaza, C-1, Block G,

Bandra Kurla Complex,

Bandra (E)

Mumbai – 400 051

Symbol: JAGSNPHARM

Dear Sir/ Madam,

Sub: Intimation under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR)

We wish to inform you that the Board of Directors at their meeting held today has approved changes in KMPs authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s) under the SEBI LODR. The contact details of the KMPs authorized is as under:

Name of KMP	Designation	Contact details
Mr. Manish Gupta	Managing Director	Tel No. 011-46181100-458
Mr. S.V. Subha Rao	Chief Financial Officer	Email id: cs@jagsonpal.com
Ms. Nandita Singh	Company Secretary	

We request you to take the above on record.

Thanking you,

Yours faithfully,

For Jagsonpal Pharmaceuticals Limited

Nandita Singh

Company Secretary and Compliance Officer